Spots Global Cancer Trial Database for A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
Official Title: A Multi-center, Randomized, Pilot Trial to Evaluate the My Hematology Oncology Patient Experience (MYHOPE™) for Multiple Myeloma (MM) Digital Care Network in Patients With MM
Study ID: NCT04730505
Conditions
Study Description
Brief Summary: NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools and resources to support the patient throughout their overall experience with MM.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mitchell Cancer Center, University of South Alabama, Mobile, Alabama, United States
Mayo Cliinic - Scottsdale, Scottsdale, Arizona, United States
University of Arizona, Tucson, Arizona, United States
James R Berenson MD Inc, West Hollywood, California, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Cancer Specialists of North Florida - Jacksonville, Jacksonville, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Augusta University - Georgia Cancer Center, Augusta, Georgia, United States
Innovation Clinical Research of the Pacific, Honolulu, Hawaii, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
American Oncology Partner Maryland, Bethesda, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Western Michigan Cancer Center, Kalamazoo, Michigan, United States
Newland Medical Associates, PC, Southfield, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Hattiesburg Clinic, Hattiesburg, Mississippi, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
NY Cancer and Blood Specialists, Port Jefferson Station, New York, United States
Rochester General Hospital - Lipson Cancer Institute, Rochester, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
Cone Health Cancer Center, Greensboro, North Carolina, United States
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
Tri County Hematology Oncology, Canton, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States
Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Cancer Care Associates of York, York, Pennsylvania, United States
West Cancer Center, Germantown, Tennessee, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Community Cancer Trials of Utah, Ogden, Utah, United States
Contact Details
Name: Catherine Ludwig
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
